| BACKGROUND:Tongue squamous cell carcinoma is the most common malignant tumor of oral and maxillofacial. At present, many using surgery, radiotherapy and chemotherapy based comprehensive treatment,but the prognosis is poor. In order to improve the efficacy of the comprehensive treatment of the cancer, in recent years, Using tumor-testis antigens as therapeutic targets for immune therapy has become a hot international medical research. And the NY-ESO-1 is considered the most immunogenic CT antigens. It can cause cellular and humoral immunity, and is widely expressed in many types of tumors. And it is the most promising CT antigens.However,the expression of NY-ESO-1 protein in TACC is not clear.OBJACTIVE:To detect the expression of Cancer-Testis antigen NY-ESO-1 in human tongue squamous cell carcinoma(TSCC),in order to analyze its expression patterns with clinicopathologic parameters and to explore it as a possible therapeutic targets immune of TSCC.METHODS:Immunohistochemical EnVision techniques was used to analyze the NY-ESO-1 expression in 53 cases of TSCC and 10 cases of normal tongue mucosa.Statistical analysis was done with SPSS.RESULTS:Expression of NY-ESO-1 was observed in 13 cases of 53 samples(24.5%),but none in normal tongue mucosa. The expression of NY-ESO-1 was significantly associated with pathological grade and tumor size,but not with positive lymph node status and tumor infiltration depth.CONCLUSION: 1. NY-ESO-1 protein has higher expression in the well differentiated and the bigger tumor tissues of TSCC. It can be further explored as one of the basic research in multivalent vaccine immunotherapy of TSCC. |
PDF Full Text Request